Salt-inducible kinases (SIKs) have recently emerged as key regulators of oncogenesis, inflammation, and immune responses, making these enzymes an important drug target. The isoform SIK3 is a novel regulator of tumor-intrinsic resistance to cytotoxic T cell attack. To support the discovery of novel SIK3 modulators, WuXi AppTec offers an integrated platform of ready-to-go biophysical assays …Read More >

Cereblon (CRBN) forms an E3 ligase complex together with DDB1, CUL4, and RBX1. CRBN functions as a substrate receptor of this complex for the recognition and binding of proteins targeted for ubiquitination and proteasomal degradation.  To support the discovery of CRBN-DDB1 proteolysis-targeting chimeras and molecular glues, WuXi AppTec offers an integrated platform of ready-to-go assays …Read More >

The adaptor protein STING (stimulator of interferon genes) has emerged as an exciting target for both immunological conditions (STING inhibition) and cancer therapies (STING activation).  To support drug discovery teams in the discovery of novel modulators of STING, WuXi AppTec offers an integrated platform of ready-to-go biophysical assays and Dianthus, a plate-based and microfluidics-free affinity …Read More >

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening.  Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies.  Leverage our portfolio of reporter cell lines to accelerate your research! …Read More >

Leverage our panel of in vitro immunology assays to accelerate your lead optimization efforts.  WuXi AppTec offers a comprehensive platform of immune profiling services, including ligand/receptor binding for target validation and cell-based functional assays to characterize both innate and adaptive immune responses. Our end-to-end services panel includes suppressive assays, mixed lymphocyte reactions, mast cell degranulation assays, …Read More >

To accelerate screening and lead optimization efforts involving immune cell differentiation, WuXi AppTec offers a comprehensive CD34+ hematopoietic stem cell differentiation platform.  Our panel includes neutrophil, eosinophil, erythroid, and mast cell differentiation, as well as monocyte/macrophage differentiation and polarization, and megakaryocyte/platelet differentiation. Check out our comprehensive platform of immune profiling and biomarker services

Comprehensive portfolio of drug resistant models representing clinically relevant mechanisms of resistance: 10+ cancer types 25+ key targets 30+ leading drugs 100+ resistant models Extensive validation data Our capabilities include cutting-edge bioinformatics and analytical techniques to enable a clear and in-depth understanding of resistance mechanisms View our AACR poster describing the establishment of a wide …Read More >

Offering a wide range of targeted oncology services and translational models.  Our comprehensive platform includes: in vitro biochemical, biophysical, and cell-based assays, including 600+ human cancer cell lines 70+ PDX-derived cell lines SPR, HTRF, ELISA, and FRET techniques ex vivo PD analysis, including: histopathology services NGS Flow cytometry Gene/protein expression analysis in vivo tumor models, …Read More >

Providing a comprehensive panel of large animal disease models across multiple species, including NHP, mini-pig, dog, and rabbit. Models for a wide range of indications, including autoimmune and inflammatory diseases Covering healthy animals, disease models, and animal biobank Multi-disciplinary read-outs (including clinical and pathology scoring, and medical imaging via MRI, X-ray, and endoscopy) Druggability assessment …Read More >